IMVTImmunovant Sciences GmbHSigning up patients
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
8Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +8.3
4 insiders sold shares within a month
Since Oct 21, 2026 · was worth 10, fading over time
Worry score8
Score over time
- Stage
- Phase 3
- Patients
- 231 (planned)
- Started
- May 27, 2025
- Main results expected
- Dec 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline in MG-ADL Score for Antibody-positive Participants
Measured over: Baseline to Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 8.3, since 2026-10-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07039916 · record last updated 2026-07-30 · checked 2026-11-09 15:42 UTC